The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 14 April 2026•Updated 16 April 2026•

1 min read

Tempus AI Shares Climb 3% on Expanded Strategic Oncology Deal with Gilead Sciences

Key Facts

1Tempus AI and Gilead Sciences expanded a multi-year collaboration to advance oncology R&D using the AI-driven Lens platform.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: Updated the story to include details regarding the new partnership with Predicta Biosciences to commercialize the GenoPredicta whole-genome sequencing assay.

Tempus AI and Gilead Sciences have expanded their strategic collaboration to accelerate oncology research using the AI-driven Lens platform and real-world evidence. Building on this momentum, Tempus AI also announced a new partnership with Predicta Biosciences for the commercial expansion of GenoPredicta, a co-branded whole-genome sequencing (WGS) assay. This new collaboration specifically targets hematologic malignancies and minimal residual disease (MRD) monitoring through advanced diagnostic solutions. These strategic moves aim to optimize clinical trial designs and biomarker strategies to enhance precision medicine in cancer treatment. Following these developments, Tempus AI shares rose by 3% as investors reacted positively to the company's growing footprint in AI-integrated healthcare and advanced diagnostics.